Citadel Advisors’s Adamas Pharmaceuticals ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-27,776
| Closed | -$136K | – | 15462 |
|
|
2021
Q3 | $136K | Buy |
27,776
+12,649
| +84% | +$61.4K | ﹤0.01% | 12497 |
|
|
2021
Q2 | $80K | Sell |
15,127
-27,419
| -64% | -$142K | ﹤0.01% | 13082 |
|
|
2021
Q1 | $204K | Buy |
+42,546
| New | +$222K | ﹤0.01% | 11659 |
|
|
2020
Q4 | – | Sell |
-23,241
| Closed | -$99.5K | – | 11774 |
|
|
2020
Q3 | $96K | Buy |
+23,241
| New | +$89.9K | ﹤0.01% | 9294 |
|
|
2020
Q2 | – | Sell |
-19,232
| Closed | -$56.5K | – | 10793 |
|
|
2020
Q1 | $55K | Sell |
19,232
-21,922
| -53% | -$98.2K | ﹤0.01% | 8993 |
|
|
2019
Q4 | $155K | Buy |
41,154
+8,553
| +26% | +$40.9K | ﹤0.01% | 8345 |
|
|
2019
Q3 | $167K | Sell |
32,601
-3,991
| -11% | -$24.6K | ﹤0.01% | 8247 |
|
|
2019
Q2 | $226K | Buy |
36,592
+11,085
| +43% | +$63.8K | ﹤0.01% | 8018 |
|
|
2019
Q1 | $181K | Sell |
25,507
-11,516
| -31% | -$104K | ﹤0.01% | 8278 |
|
|
2018
Q4 | $316K | Sell |
37,023
-3,343
| -8% | -$43.5K | ﹤0.01% | 7173 |
|
|
2018
Q3 | $808K | Buy |
40,366
+12,162
| +43% | +$286K | ﹤0.01% | 5916 |
|
|
2018
Q2 | $729K | Buy |
28,204
+8,524
| +43% | +$236K | ﹤0.01% | 5758 |
|
|
2018
Q1 | $470K | Sell |
19,680
-273,453
| -93% | -$8.62M | ﹤0.01% | 5981 |
|
|
2017
Q4 | $9.93M | Sell |
293,133
-488,432
| -62% | -$13.6M | 0.01% | 1741 |
|
|
2017
Q3 | $16.5M | Buy |
781,565
+746,937
| +2,157% | +$13.7M | 0.01% | 1213 |
|
|
2017
Q2 | $606K | Buy |
+34,628
| New | +$573K | ﹤0.01% | 4849 |
|
|
2016
Q4 | – | Sell |
-13,323
| Closed | -$219K | – | 8078 |
|
|
2016
Q3 | $219K | Buy |
+13,323
| New | +$203K | ﹤0.01% | 6184 |
|
|
2016
Q2 | – | Sell |
-108,747
| Closed | -$1.57M | – | 7617 |
|
|
2016
Q1 | $1.57M | Sell |
108,747
-120,601
| -53% | -$2.03M | ﹤0.01% | 2925 |
|
|
2015
Q4 | $6.5M | Buy |
+229,348
| New | +$3.86M | 0.01% | 1593 |
|
|
2015
Q3 | – | Sell |
-16,341
| Closed | -$428K | – | 9373 |
|
|
2015
Q2 | $428K | Sell |
16,341
-22,611
| -58% | -$440K | ﹤0.01% | 5220 |
|
|
2015
Q1 | $682K | Sell |
38,952
-4,254
| -10% | -$72.9K | ﹤0.01% | 4468 |
|
|
2014
Q4 | $751K | Buy |
43,206
+20,475
| +90% | +$311K | ﹤0.01% | 4149 |
|
|
2014
Q3 | $423K | Buy |
+22,731
| New | +$391K | ﹤0.01% | 4840 |
|
Citadel Advisors's ADMS Position: Q4 2021 in Review
Citadel Advisors sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 27,776 shares — an estimated $136K sold.
Citadel Advisors first reported a position in ADMS in Q3 2014 and held it in 23 quarters. The position peaked at $16.5M in Q3 2017. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.
- Citadel Advisors reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- Citadel Advisors sold 27,776 Adamas Pharmaceuticals shares in Q4 2021, an estimated $136K.
- Citadel Advisors first reported a position in Adamas Pharmaceuticals in Q3 2014 and held it in 23 quarters.
- Citadel Advisors's Adamas Pharmaceuticals position peaked at $16.5M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.
Based on Citadel Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.